JO
SRPT icon

John Overdeck’s Sarepta Therapeutics SRPT Stock Holding History

John Overdeck’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,100
Closed -$332K – 3326
2024
Q2 		$332K Buy
+2,100
New +$270K ﹤0.01% 2550
2023
Q4 		– Sell
-8,000
Closed -$970K – 3371
2023
Q3 		$970K Buy
+8,000
New +$904K ﹤0.01% 1952

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John Overdeck's SRPT Position: Q2 2026 in Review

John Overdeck increased its Sarepta Therapeutics (SRPT) stake by 0.12% in Q2 2026, buying an estimated $105K and bringing the position to 4,598,735 shares worth $82.6M. The position accounts for 0.06% of the portfolio, ranked #368.

John Overdeck first reported a position in SRPT in Q3 2015 and has held it in 26 quarters since. The position peaked at $151M in Q1 2023. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • John Overdeck held 4,598,735 shares of Sarepta Therapeutics worth $82.6M as of Q2 2026.
  • John Overdeck bought 5,540 Sarepta Therapeutics shares in Q2 2026, an estimated $105K.
  • Sarepta Therapeutics made up 0.06% of John Overdeck's portfolio in Q2 2026, its #368 holding.
  • John Overdeck first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 26 quarters since.
  • John Overdeck's Sarepta Therapeutics position peaked at $151M in Q1 2023.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.